RA Capital Management - ALPINE IMMUNE SCIENCES INC ownership

ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 64 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.6%.

Quarter-by-quarter ownership
RA Capital Management ownership history of ALPINE IMMUNE SCIENCES INC
ValueSharesWeighting
Q3 2023$53,713,988
+11.4%
4,691,1780.0%1.06%
+16.0%
Q2 2023$48,225,310
+33.2%
4,691,178
+0.1%
0.91%
+11.2%
Q1 2023$36,192,248
+12.0%
4,688,115
+6.6%
0.82%
+25.0%
Q4 2022$32,320,655
+3.0%
4,397,368
+0.9%
0.66%
-2.1%
Q3 2022$31,368,0004,356,6320.67%
Other shareholders
ALPINE IMMUNE SCIENCES INC shareholders Q4 2022
NameSharesValueWeighting ↓
Decheng Capital Management III (Cayman), LLC 6,708,288$76,809,89825.63%
Lynx1 Capital Management LP 2,404,614$27,532,83018.21%
GREAT POINT PARTNERS LLC 3,078,633$35,250,3486.42%
Ghost Tree Capital, LLC 664,132$7,604,3112.50%
Frazier Life Sciences Management, L.P. 2,985,757$34,186,9182.27%
Paradigm Biocapital Advisors LP 2,421,743$27,728,9571.88%
COMMODORE CAPITAL LP 1,325,000$15,171,2501.77%
Nan Fung Group Holdings Ltd 182,280$2,087,1061.69%
Omega Fund Management, LLC 153,700$1,759,8651.62%
Octagon Capital Advisors LP 750,000$8,587,5001.32%
View complete list of ALPINE IMMUNE SCIENCES INC shareholders